
Ocugen, Inc. (NASDAQ:OCGN – Free Report) – Stock analysts at Noble Financial lifted their FY2026 earnings estimates for Ocugen in a research report issued on Wednesday, November 11th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings of ($0.16) per share for the year, up from their prior estimate of ($0.26). The consensus estimate for Ocugen’s current full-year earnings is ($0.19) per share.
Other analysts have also recently issued research reports about the company. Wall Street Zen raised Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocugen in a report on Wednesday, November 4th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.50.
Ocugen Price Performance
Shares of OCGN opened at $0.83 on Friday. The firm has a market cap of $280.88 million, a PE ratio of -4.14 and a beta of 2.04. The firm’s 50 day moving average price is $0.94 and its 200 day moving average price is $1.39. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.77 and a current ratio of 0.77. Ocugen has a twelve month low of $0.69 and a twelve month high of $2.73.
Insiders Place Their Bets
In other Ocugen news, CEO Shankar Musunuri sold 57,264 shares of the firm’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $0.95, for a total value of $54,400.80. Following the sale, the chief executive officer owned 1,030,771 shares of the company’s stock, valued at $979,232.45. This trade represents a 5.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,051,982 shares of company stock worth $1,088,801. 3.95% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Ocugen
Hedge funds have recently modified their holdings of the business. Diversify Advisory Services LLC acquired a new stake in shares of Ocugen in the second quarter worth $25,000. GTS Securities LLC acquired a new position in Ocugen during the 2nd quarter valued at $27,000. Engineers Gate Manager LP raised its stake in Ocugen by 70.2% during the 2nd quarter. Engineers Gate Manager LP now owns 18,368 shares of the company’s stock valued at $28,000 after purchasing an additional 7,577 shares during the last quarter. CTC Alternative Strategies Ltd. bought a new stake in Ocugen in the 1st quarter valued at $34,000. Finally, Kovack Advisors Inc. bought a new stake in Ocugen in the 3rd quarter valued at $34,000. 10.27% of the stock is owned by institutional investors.
About Ocugen
Ocugen, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases and other eye conditions. Its approach includes modifier gene therapies designed to address multiple genetic causes of disease, rather than targeting a single mutation. The company’s clinical programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease. These programs are investigational and are not approved treatments.
Featured Stories
- Five stocks we like better than Ocugen
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
